Lee Su-hyun, the female vocalist of the popular South Korean duo AKMU (Akdong Musician), has publicly addressed and dismissed circulating rumors suggesting she used Wegovy, a prescription weight-loss medication, to achieve her recent physical transformation. The 25-year-old singer took to social media to clarify the speculation that had been spreading among fans and online communities.

The rumors began circulating after fans noticed Lee Su-hyun's noticeably slimmer appearance in recent public appearances and social media posts. Wegovy, known generically as semaglutide, is an FDA-approved weight management drug that has gained significant attention in recent years among celebrities and the general public for its effectiveness in promoting weight loss when combined with diet and exercise.

In her statement, Lee Su-hyun expressed frustration with the persistent speculation about her weight loss methods and emphasized that her transformation was achieved through natural means including dietary changes and regular exercise. She stressed the importance of not spreading unverified information and asked fans to respect her privacy regarding personal health matters.

AKMU, consisting of Lee Su-hyun and her brother Lee Chan-hyuk, debuted in 2014 under YG Entertainment after winning the second season of the survival show "K-pop Star." The duo has maintained a strong fanbase throughout their career, known for their unique musical style and authentic performances. This latest controversy highlights the intense scrutiny that K-pop celebrities face regarding their physical appearance and personal lives in the highly competitive entertainment industry.